Inj dihydroergotamine mesylt
Products billed under this code include Dihydroergotamine Mesylate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Dihydroergotamine Mesylate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Dihydroergotamine Mesylate | Hikma Pharmaceuticals USA Inc. | 00143-9273-10 | 10 | $565.07 |
| Dihydroergotamine Mesylate | Padagis US LLC | 00574-0850-05 | 5 | $282.535 |
| Dihydroergotamine Mesylate | Padagis US LLC | 00574-0850-10 | 10 | $565.07 |
| Dihydroergotamine Mesylate | Apollo Pharmaceuticals Inc. | 61990-0411-01 | 5 | $282.535 |
| Dihydroergotamine Mesylate | Apollo Pharmaceuticals Inc. | 61990-0411-02 | 10 | $565.07 |
| Dihydroergotamine Mesylate | Apollo Pharmaceuticals | 81284-0411-05 | 5 | $282.535 |
| Dihydroergotamine Mesylate | Apollo Pharmaceuticals | 81284-0411-10 | 10 | $565.07 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $56.507 | +$1.529 | 1 MG | Inj dihydroergotamine mesylt | v1, posted September 17, 2026 |
| 3Q26 | $54.978 | +$0.093 | 1 MG | Inj dihydroergotamine mesylt | v1, posted September 15, 2026 |
| 2Q26 | $54.885 | −$2.197 | 1 MG | Inj dihydroergotamine mesylt | v1, posted September 15, 2026 |
| 1Q26 | $57.082 | −$2.922 | 1 MG | Inj dihydroergotamine mesylt | v1, posted September 15, 2026 |
| 4Q25 | $60.004 | −$37.069 | 1 MG | Inj dihydroergotamine mesylt | v1, posted September 8, 2026 |
| 3Q25 | $97.073 | +$11.326 | 1 MG | Inj dihydroergotamine mesylt | v1, posted March 10, 2026 |
| 2Q25 | $85.747 | +$44.71 | 1 MG | Inj dihydroergotamine mesylt | v1, posted March 10, 2026 |
| 1Q25 | $41.037 | −$7.04 | 1 MG | Inj dihydroergotamine mesylt | v1, posted December 19, 2025 |
| 4Q24 | $48.077 | +$0.963 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 11, 2025 |
| 3Q24 | $47.114 | +$9.997 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 11, 2025 |
| 2Q24 | $37.117 | −$5.224 | 1 MG | Inj dihydroergotamine mesylt | v1, posted March 11, 2025 |
| 1Q24 | $42.341 | −$4.176 | 1 MG | Inj dihydroergotamine mesylt | v1, posted December 19, 2024 |
| 4Q23 | $46.517 | −$4.071 | 1 MG | Inj dihydroergotamine mesylt | v1, posted October 10, 2024 |
| 3Q23 | $50.588 | −$7.215 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 5, 2024 |
| 2Q23 | $57.803 | +$0.488 | 1 MG | Inj dihydroergotamine mesylt | v1, posted February 23, 2024 |
| 1Q23 | $57.315 | −$0.785 | 1 MG | Inj dihydroergotamine mesylt | v1, posted December 6, 2023 |
| 4Q22 | $58.10 | −$0.136 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 22, 2023 |
| 3Q22 | $58.236 | +$1.222 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 9, 2023 |
| 2Q22 | $57.014 | +$2.085 | 1 MG | Inj dihydroergotamine mesylt | v1, posted December 14, 2022 |
| 1Q22 | $54.929 | +$7.509 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 8, 2022 |
| 4Q21 | $47.42 | +$3.947 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 2, 2022 |
| 3Q21 | $43.473 | −$13.003 | 1 MG | Inj dihydroergotamine mesylt | v1, posted June 2, 2022 |
| 2Q21 | $56.476 | −$0.76 | 1 MG | Inj dihydroergotamine mesylt | v1, posted March 1, 2022 |
| 1Q21 | $57.236 | – | 1 MG | Inj dihydroergotamine mesylt | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.